Your browser doesn't support javascript.
loading
Transcriptomic Analysis of Hepatitis B Infected Liver for Prediction of Hepatocellular Carcinoma.
Karaoglu, Diren Arda; Uner, Meral; Simsek, Cem; Gure, Ali Osmay; Demirkol-Canli, Secil.
Afiliação
  • Karaoglu DA; Faculty of Medicine, Hacettepe University, 06100 Ankara, Turkey.
  • Uner M; Department of Pathology, Hacettepe University Faculty of Medicine, Sihhiye, 06100 Ankara, Turkey.
  • Simsek C; Department of Gastroenterology, Hacettepe University Faculty of Medicine, 06100 Ankara, Turkey.
  • Gure AO; Department of Medical Biology, Acibadem University, 34684 Istanbul, Turkey.
  • Demirkol-Canli S; Molecular Pathology Application and Research Center, Hacettepe University, 06100 Ankara, Turkey.
Biology (Basel) ; 12(2)2023 Jan 26.
Article em En | MEDLINE | ID: mdl-36829466
ABSTRACT
Hepatocellular cancer (HCC) is a leading cause of cancer-related mortality worldwide, and chronic hepatitis B virus infection (CHB) has been a major risk factor for HCC development. The pathogenesis of HBV-related HCC has been a major focus revealing the interplay of a multitude of intracellular signaling pathways, yet the precise mechanisms and their implementations to clinical practice remain to be elucidated. This study utilizes publicly available transcriptomic data from the livers of CHB patients in order to identify a population with a higher risk of malignant transformation. We report the identification of a novel list of genes (PCM1) which can generate clear transcriptomic sub-groups among HBV-infected livers. PCM1 includes genes related to cell cycle activity and liver cancer development. In addition, markers of inflammation, M1 macrophages and gamma delta T cell infiltration are present within the signature. Genes within PCM1 are also able to differentiate HCC from normal liver, and some genes within the signature are associated with poor prognosis of HCC at the mRNA level. The analysis of the immunohistochemical stainings validated that proteins coded by a group of PCM1 genes were overexpressed in liver cancer, while minimal or no expression was detected in normal liver. Altogether, our findings suggest that PCM1 can be developed into a clinically applicable method to identify CHB patients with a higher risk of HCC development.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Biology (Basel) Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Biology (Basel) Ano de publicação: 2023 Tipo de documento: Article